With Price-Increase Clauses, These Two Drug Distributors Can Withstand ‘Trumpflation’
McKesson (MCK) and Cencora (COR) benefit from drug price increases due to inflation-based compensation clauses. McKesson reported $403.4B revenue in 2026, up 12%, and raised EPS guidance. Cencora posted $321.3B revenue in 2025, up 3.8%, and increased EPS guidance. Both companies' contracts allow gains from manufacturer price hikes, but risks include regulation and cost pressures.
How this was made
The 30-second read
Why it matters
Both companies raised EPS guidance, indicating stronger earnings potential amid higher drug prices, which may attract investors seeking inflation hedges.
Market read
Guidance upgrades for two large‑cap drug distributors suggest they could outperform in a high‑inflation environment, offering a sector‑specific play.
What to watch
Higher transportation and labor costs may offset inflation gains; potential policy changes could curb price‑increase clauses.
Background
The article discusses how drug distributors McKesson and Cencora can benefit from inflation‑driven drug price increases, citing recent earnings and guidance upgrades.
Ticker impact
McKesson raised full‑year adjusted EPS guidance to $44.20‑$45.00 after reporting FY2026 revenue up 12% and Q1 FY2027 revenue up 8%.
Potential upside of 5‑10% on near‑term basis.
Higher guidance on a large‑cap distributor with inflation‑linked contracts suggests earnings beat expectations.
Cencora lifted full‑year adjusted EPS guidance to $17.65‑$17.90 after FY2025 revenue of $321.3B and Q1 revenue up 3.8%.
Potential upside of 4‑8% in the short term.
Guidance beat on a major distributor with inflation‑linked contracts suggests earnings momentum.
Market effects
Drug distributors may outperform in an inflationary environment, benefiting the broader healthcare distribution sector.
U.S. healthcare supply chain gains visibility, supporting related equities.
Inflation‑linked contracts could make similar distributors worldwide attractive.
Counterpoint
Rising drug prices could trigger regulatory backlash or generic competition, limiting upside.
Key entities
- CompanyMcKesson
U.S. pharmaceutical distributor (ticker MCK).
- CompanyCencora
U.S. pharmaceutical distributor (ticker COR).
